Clinical Trials
13 trialsNCT06596473 2026-06-04
A Study of BG-C477 in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT05981703 2026-06-03
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07414836 2026-06-03
A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT07331155 2026-05-18
A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT07390383 2026-05-13
A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]
Nanjing Leads Biolabs Co.,Ltd
Phase 2 Recruiting
NCT06349837 2026-05-01
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
Sichuan University
Phase 1 Recruiting
NCT03736889 2026-04-22
Tislelizumab (Anti-Programmed Cell Death Protein-1 (PD-1) Antibody) in MSI-H or dMMR Solid Tumors
BeOne Medicines
Phase 2 Recruiting
NCT06233942 2026-04-15
Phase 1a/1b First-in-Human Study of BG-C9074 Alone and in Combination With Other Anticancer Therapies in Patients With Advanced Solid Tumors
BeOne Medicines
Phase 1 Recruiting
NCT05547321 2025-11-25
Efficacy and Safety Study of OMTX705, Monotherapy and Anti-PD-1-combined, in Subjects With Advanced Solid Tumors.
Oncomatryx Biopharma S.L.
Phase 1 Recruiting
NCT05978102 2025-07-23
A Dose Escalation and Dose Expansion Clinical Study of STI-7349 in Subjects With Advanced Solid Tumors
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Phase 1/2 Recruiting
NCT06541639 2025-03-18
EVM16 Injection As a Single and Combination with Tislelizumab in Solid Tumors
Peking University
Phase 1 Recruiting
NCT06032845 2025-02-27
CASTLE-11
Fudan University
Phase 2 Recruiting
NCT05699811 2023-04-28
IFNα Expressing Mesenchymal Stromal Cells for Locally Advanced/Metastatic Solid Tumors
Chinese PLA General Hospital
Phase 1/2 Recruiting